Tacrolimus Envarsus Xr denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for tacrolimus envarsus xr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Tacrolimus Envarsus XR for Medical Necessity

A medical-necessity denial from Cigna means the plan's reviewers concluded the submitted documentation did not establish that Envarsus XR is required for your condition under Cigna's coverage criteria. For transplant immunosuppression, this denial most commonly occurs when the clinical record submitted at prior authorization was sparse — missing trough-level variability history, tolerability data, or a direct explanation of why the extended-release formulation is clinically necessary rather than simply preferred.

Medical-necessity denials for FDA-approved transplant medications are among the most appealable denial types. Transplant care is high-stakes, and the standard of care supported by major transplant medicine societies provides strong clinical grounding for appeals.

## Your Federal Appeal Rights

• Internal appeal: You have the right to an internal appeal within the timeframe on your denial notice. Cigna must provide a full written explanation of the clinical rationale and the criteria applied.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review — generally within approximately four months of the final internal denial. An independent clinician, not employed by Cigna, will evaluate the medical-necessity determination.
• ERISA §503: If your plan is employer-sponsored, ERISA entitles you to a full-and-fair review including access to all documents used in the decision.
• Expedited review: If immunosuppression stability is at risk, the expedited track (typically 72-hour turnaround) is available. Request it at the same time you file the appeal.

## What to Gather

1. Transplant and diagnosis records: Operative notes, transplant date, organ type, and current immunosuppression protocol. 2. Tacrolimus history with dates and outcomes: A chronological summary of all tacrolimus formulations tried, with dates, trough levels, and documented outcomes — including any episodes of elevated variability, rejection, or toxicity. 3. Clinical severity documentation: Recent clinic notes, lab trends, and any biopsy results relevant to your transplant stability. 4. Prescriber medical-necessity letter: The single most important document. Your transplant physician should explain, point by point, how your clinical situation meets each criterion in Cigna's coverage policy, referencing the FDA-approved prescribing information for Envarsus XR and the applicable transplant society guideline organization.

## Criteria-Mapping Structure

Download Cigna's current coverage policy for Envarsus XR or extended-release tacrolimus from their policy library at cigna.com. List every coverage criterion. For each one, record the exact chart fact that satisfies it:

| Cigna Medical-Necessity Criterion | Supporting Chart Documentation | |---|---| | [Criterion from Cigna policy] | [Clinic note date / lab value / prescriber attestation] |

Submit this table as an exhibit to your appeal letter. Reviewers — including external reviewers — respond most favorably to appeals that directly answer each criterion rather than submitting records without narrative framing.